ESTRASORB
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ESTRASORB (ESTRASORB).
Estradiol, the primary estrogen component, binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene transcription and protein synthesis to replace deficient endogenous estrogen, alleviating menopausal symptoms.
| Metabolism | Primarily hepatic via cytochrome P450 enzymes (CYP3A4 and CYP1A2) to less active metabolites (estrone, estriol, catechol estrogens). Undergo enterohepatic recirculation. |
| Excretion | Estradiol and its metabolites are primarily excreted in urine (about 90%) and feces (about 10%). Biliary excretion contributes to fecal elimination. Renal clearance accounts for the majority of systemic clearance. |
| Half-life | The terminal elimination half-life for estradiol is approximately 12-14 hours. This supports once-daily or twice-weekly dosing intervals for transdermal systems like ESTRASORB. |
| Protein binding | Approximately 98% of circulating estradiol is bound to sex hormone-binding globulin (SHBG) and albumin. SHBG binds about 60-65%, albumin about 30-35%. |
| Volume of Distribution | The apparent volume of distribution of estradiol is approximately 1.2 L/kg, indicating extensive distribution into tissues (including breast, uterus, and adipose tissue). |
| Bioavailability | Transdermal absorption bypasses first-pass hepatic metabolism, providing approximately 100% systemic bioavailability relative to the amount released from the patch (actual absorption ~10-15% of applied dose due to residual patch content). |
| Onset of Action | Serum estradiol levels rise within 4-8 hours after application of ESTRASORB; clinical effects (e.g., vasomotor symptom reduction) are typically observed within 2-4 weeks of starting therapy. |
| Duration of Action | Sustained estradiol levels are maintained over the 7-day wear period of the transdermal system. Clinical effects such as relief of menopausal symptoms persist with continuous use; effects wane within days after removal. |
One or two 0.87 mg estradiol transdermal packets (0.87 mg to 1.7 mg estradiol per day) applied once daily to the upper thigh or upper arm. Rotate application sites.
| Dosage form | EMULSION |
| Renal impairment | No specific dosage adjustment recommended; use with caution in patients with renal impairment as limited data available. |
| Liver impairment | Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). For mild-to-moderate impairment (Child-Pugh A or B), initiate at lowest dose and monitor; no specific dosing guidelines due to limited data. |
| Pediatric use | Safety and efficacy not established in pediatric patients; not indicated for use in this population. |
| Geriatric use | Use lowest effective dose for shortest duration; increased risk of cardiovascular events, thromboembolism, and dementia in women aged 65 years and older. Initiate at 0.87 mg once daily if deemed appropriate. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ESTRASORB (ESTRASORB).
| Breastfeeding | Estradiol is excreted in breast milk in small amounts; M/P ratio approximately 0.4-0.6. Can suppress lactation and reduce milk production. Breastfeeding not recommended during use due to potential adverse effects on infant development. |
| Teratogenic Risk | Estradiol (Estrasorb) is contraindicated in pregnancy. First trimester exposure associated with urogenital tract abnormalities and possible congenital heart defects. Second and third trimester exposure linked to female genital tract anomalies in offspring (e.g., vaginal adenosis, cervical abnormalities) and potential neurodevelopmental effects. Estrogens increase fetal risk of reproductive tract malformations. |
■ FDA Black Box Warning
Estrogens should not be used to prevent cardiovascular disease or dementia. Increased risk of endometrial cancer in women with intact uterus. Increased risk of stroke, deep vein thrombosis, pulmonary embolism, and myocardial infarction. Increased risk of probable dementia in postmenopausal women aged 65 years and older. Breast cancer risk may increase with use.
| Serious Effects |
["Undiagnosed abnormal genital bleeding","Known, suspected, or history of breast cancer","Known or suspected estrogen-dependent neoplasia","Active DVT, PE, or history of these conditions","Active arterial thromboembolic disease or history of stroke, MI","Known anaphylactic reaction or angioedema to estradiol","Liver impairment or disease","Known protein C, protein S, or antithrombin deficiency or other thrombophilic disorders","Pregnancy"]
| Precautions | ["Cardiovascular disorders: increased risk of stroke, DVT, PE, MI","Malignant neoplasms: endometrial cancer, breast cancer (risk increases with duration of use)","Dementia: probable increased risk in women ≥65 years","Gallbladder disease","Hypertriglyceridemia","Fluid retention","Hypocalcemia","Hereditary angioedema","Exacerbation of endometriosis","Exacerbation of asthma, diabetes, epilepsy, migraine, porphyria, lupus erythematosus, hepatic hemangiomas","Retinal vascular thrombosis","Discontinue prior to surgery or prolonged immobilization"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, signs of thrombotic events, and liver function. Serial ultrasound for fetal growth if inadvertent exposure occurs. No specific fetal monitoring indicated for therapeutic use as pregnancy is contraindicated. |
| Fertility Effects | Exogenous estrogens may disrupt normal menstrual cycle and ovulation, potentially reducing fertility. Reversible upon discontinuation. |